Axogen

Quote

































































What is Amniovo?
http://www.tristatebiologics.com/amniovo.html
Amniovo is a composite amniotic tissue membrane minimally manipulated to protect the collagen matrix and its natural properties. Amniovo reduces scar tissue formation, reduces inflammation in the surgical site, enhances healing, and acts as a barrier.

Human amniotic membrane comprises the innermost layer of the placenta and lines the amniotic cavity. Amniovo is processed through the proprietary PURION® Process that combines cleaning, dehydration and sterilization, and it may be stored at ambient conditions for up to 5 years. The proprietary PURION® Process protects the delicate scaffold during processing, leaving an intact collagen matrix. The result is a durable graft with natural barrier properties to optimize surgical performance and ease of use. Amniovo is available in sheet/membrane, particulate, and wrap configurations for use in surgical, soft tissue, tendon, and nerve applications.
 








Looks like they cut commissions again and made the lamotrigine rep who sexually harassed female employees a manager in Georgia. On a more positive note they finally promoted from within with some good people getting better positions and even fired one of the Possis guys. It'll be curious to see if that changes morale in FL at the end of the year meeting and who decides its time to update their resume.
 








It's only a 3% decrease. With the 9000% increase in quotas coming we'll be rolling in dough as long as we simply make quota. The pending price increase will definitely help as our customers are clamoring for an ass raping. After all, it is what the market will bear.
 
























ALACHUA, Fla., Jan. 05, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Ivica (Ivan) Ducic, M.D., Ph.D. as Medical Director of Clinical and Translational Sciences. Dr. Ducic will be responsible for AxoGen's global medical affairs programs as a non-officer member of the leadership team.

“The addition of Dr. Ducic to our Clinical and Translational Sciences team will enhance our efforts to provide world class surgeon education, meaningful clinical evidence on our product portfolios, and continued innovation in peripheral nerve repair technology,” commented Karen Zaderej, President and Chief Executive Officer. “Dr. Ducic is a renowned and experienced peripheral nerve surgeon who shares our mission to improve the quality of life for patients suffering from peripheral nerve injuries.”

Dr. Ducic is a Board Certified Plastic Surgeon with additional training and expertise in peripheral nerve surgery. He received his medical degree in 1991 from the University of Zagreb School of Medicine (Croatia, Europe), and a Ph.D. degree in 1995 in Neuroscience. Upon completing plastic surgery training at Georgetown University Hospital in 2002, he entered a one-year peripheral nerve surgery fellowship. He then joined the full-time faculty practice at Georgetown University Hospital Department of Plastic Surgery in August 2003, where he served as the Professor of Plastic Surgery and Neurosurgery and he is the Founder/Director of their Peripheral Nerve Surgery Institute. Dr. Ducic established his own practice in 2014, the Washington Nerve Institute in McLean, VA, where he continues to practice today. Among his many accomplishments, Dr. Ducic is the past president of American Society for Peripheral Nerve. He has also served on many committees, served as journal editor for peripheral nerve focused research, published over 90 peer-reviewed papers, authored 15 book chapters, and has been a prolific educator both nationally and internationally on the diagnosis and treatment of peripheral nerve injury.
 








anonymous said:
Looks like they cut commissions again and made the lamotrigine rep who sexually harassed female employees a manager in Georgia. On a more positive note they finally promoted from within with some good people getting better positions and even fired one of the Possis guys. It'll be curious to see if that changes morale in FL at the end of the year meeting and who decides its time to update their resume.
Click to expand...
When have they not cut commissions each year? They spin it like the quota eclipsing contests will help you make up the difference before they throw out their baseless quota's. In reality, very few reps will make more money year over year...especially when compared to upper management's pay increases. If the company wasnt consistently still losing over $10mil year, one could justify giving upper mgmt a raise. It's time their upper mgmt start leading by example.
 
















anonymous said:
Very interesting comments concerning management compensation. When employees leave Axogen are their stock options granted to management?
Click to expand...
Dont think options go to mgmt. after a rep leaves. A pre release of 2016 financials just came out. Revenues are projected to be $41mil generated from 51 direct reps and 20 distributors. They conveniently "forgot" to mention that they spent over $50mil resulting in a net loss of $10mil. However, they're only in the very early stages of converting a $1.6 billion nerve repair mkt. :)
 
















Big year for Axogen... do sales continue to climb at the same impressive rate or do they begin flattening? Will facilities continue to allow yearly price increases for implants without specific reimbursement?
 
















Top Bottom
Back
Quote